S
Silvio E. Inzucchi
Researcher at Yale University
Publications - 511
Citations - 64889
Silvio E. Inzucchi is an academic researcher from Yale University. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 92, co-authored 424 publications receiving 54101 citations. Previous affiliations of Silvio E. Inzucchi include University of Toronto & American Diabetes Association.
Papers
More filters
Journal ArticleDOI
Combination alogliptin plus pioglitazone treatment in patients with type 2 diabetes inadequately controlled with diet exercise
Julio Rosenstock,Silvio E. Inzucchi,Jochen Seufert,Penny R. Fleck,Craig A. Wilson,Qais Mekki +5 more
Journal ArticleDOI
Baseline characteristics of participants enrolled in the empagliflozin cardiovascular outcome trial (EMPA-REG OUTCOME™) in patients with type 2 diabetes
B. Zinman,Silvio E. Inzucchi,JM Lachin,Christoph Wanner,R Ferrari,David Fitchett,E Bluhmki,J Kempthorne-Rawson,J. Newman,OE Johansen,HJ Woerle,Uli C. Broedl +11 more
Journal ArticleDOI
Lbps 02-52 effect of empagliflozin on heart failure outcomes in subgroups by age: results from empa-reg outcome
Dae Wook Lee,Pedro Monteiro,Douglas Clark,Stefan Hantel,Hans-Juergen Woerle,Silvio E. Inzucchi,David Fitchett +6 more
TL;DR: Empagliflozin, added to standard of care, reduced the risk of hospitalization for heart failure and heart failure hospitalization or cardiovascular death in patients with type 2 diabetes and high cardiovascular risk irrespective of age.
Journal ArticleDOI
A 73-year-old man with hyperglycemia, skin rashes, anemia and weight loss.
Journal ArticleDOI
Effect of treatment with dapagliflozin according to baseline systolic blood pressure in patients with hfref: an analysis of the dapa-hf trial
John J.V. McMurray,Michael Boehm,Matteo Serenelli,Silvio E. Inzucchi,Pardeep S. Jhund,Lars Køber,Mikhail Kosiborod,Anna Maria Langkilde,Felipe Martinez,Olof Bengtsson,Piotr Ponikowski,Marc S. Sabatine,Mikaela Sjoestrand,Scott D. Solomon +13 more
TL;DR: In DAPA-HF, dapagliflozin (10mg qd), vs. placebo, reduced the risk of worsening HF and CV death and was associated with worse outcomes.